Testicular Cancer Drugs Market – Global Industry Trends and Analysis from 2023
Testicular cancer is observed in males aged between 15 to 44 years where major symptoms include forming a painless lump or swelling in testicles. If the cancer is left untreated, the eventual course is metastasis and mortality. However, due to advances in multimodal treatments which include surgery, radiation and chemotherapy, a cure for this type of cancer is commonly achieved. Testicular cancer is classified into different types of cancer depending on the type cell in which cancer begins. Cancer developed in germ cells is termed as germ cell testicular cancer and is the most common type. Germ cell testicular cancers account for more than 95% of all testicular cancer cases and are further segmented into seminomas and non-seminomas which approximately account for 40% and 60% of total germ cell testicular cancer. The other less prevalent types of testicular cancers include include Leydig cell tumors (1% to 3%) and Sertoli cell tumors (less than 1%). The treatment of testicular cancer is determined on the type of cancer and the level of advancement of tumor within the body.
Get a Free Sample Report:
Testicular cancer itself is a relatively uncommon and accounts for less than 1 percent of all types of cancer incidences. Globally the cancer is more prevalent in the developed regions which include Australia, North America and Europe. In 2011, approximately 2,207 men in the U.K. were diagnosed with testicular cancer while 68 men died from this disease. The American Cancer Society estimates that in 2014 about 8,820 new cases of testicular cancer will be diagnosed and 380 deaths will occur in the U.S. The rate of incidences of testicular cancer has been observed to be rising every year across the world, however the curability of this disease has increased the survival rate of patients affecting with it. For instance, only four percent of testicular cancer patients in the U.S. die within first five years of getting the disease. Hence, more people are getting treated each year with this type of cancer which reflects the growth of the global testicular cancer drugs market.
The global testicular cancer drugs market is classified on the basis of cancer types into three segments, namely germ cell cancer drugs market, Leydig cell cancer drugs market and Sertoli cell cancers market. The main drugs used in treating testicular cancer are cisplatin, etoposide, ifosfamide, paclitaxel, and vinblastine. Other drugs used for treating testicular cancer include bleomycin, dactinomycin. The treatment is more effective if the chemotherapy regimen involve 2 or more drugs rather than using any single drug. The common chemotherapy regimens for treatment of testicular cancer are BEP (bleomycin, etoposide, and cisplatin), EP (etoposide and cisplatin), TIP (paclitaxel, ifosfamide, and cisplatin), and VIP (VP-16/etoposide or vinblastin, ifosfamide and cisplatin). Some of these drugs can have serious side effects such as kidney damage, lung damage, neuropathy, and hemorrhagic cystitis and therefore have to be administered with utmost care and monitoring the effects of these drugs. However, the side effects last shortly and do not affect the patient permanently unless the dosage regimens include very high doses for ling duration.
Some of the key players in the global testicular cancer drugs market include Bristol-Myers Squibb Co., Hospira Inc., Ovation Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., ZIOPHARM Oncology Inc., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.
Full Research Report on Global Testicular Cancer Drugs Market: